RxDoctor Payments Data

Kenneth Wals, MD

Ophthalmology · Coral Gables, FLNPI 1023057395

Payments from drug & device makers

$3,182in general payments, 2019–2025

Across 131 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Genentech USA, Inc.$420
  • Regeneron Healthcare Solutions, Inc.$371
  • Apellis Pharmaceuticals, Inc.$313
  • Alcon$205
  • Ocular Therapeutix, Inc.$94
  • plus $292 from 7 others

What the payments were for

  • Food & beverage$3,08897%
  • Education$943%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,182 in reported general payments places this provider in the 60th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$101,809
Medicare patients
77
Services billed
918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EyleaAflibercept774$1,700,409
VabysmoFaricimab-Svoa295$675,818
SyfovrePegcetacoplan/Pf103$329,872
LucentisRanibizumab141$249,177
RestasisCyclosporine153$149,629
Eylea HdAflibercept52$137,913
IlevroNepafenac302$110,067
BeovuBrolucizumab-Dbll43$86,769
AvastinBevacizumab66$61,490
LumiganBimatoprost105$42,844
XiidraLifitegrast22$30,369
RocklatanNetarsudil Mesylat/Latanoprost59$21,898
Alphagan PBrimonidine Tartrate63$21,813
Prednisolone Acetate600$20,843
CombiganBrimonidine Tartrate/Timolol53$18,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Regeneron Healthcare Solutions, Inc.Eylea, Eylea Hd$371$1,838,322826 claims
Genentech USA, Inc.Vabysmo$420$675,818295 claims
Apellis Pharmaceuticals, Inc.Syfovre$313$329,872103 claims
AbbVieRestasis, Lumigan, Alphagan P, Combigan$1,487$232,845374 claims
NovartisIlevro, Beovu$78$196,836345 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$51$36,361104 claims
AlconSimbrinza$205$10,94052 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Coral Gables

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →